Andrzej Janiszewski

Andrzej is part of the firm’s global Environmental, Social, and Governance (ESG) practice and is a founding member of the Social Impact Finance Group. Andrzej has a particular focus on the social aspects of ESG. He has been involved in ground-breaking impact investing and social impact finance deals, including an innovative financing agreement to guarantee continued production of the antigen for the world’s first malaria vaccine.

Andrzej has worked on a broad variety of structured finance transactions, including residential mortgage-backed securitisations, commercial mortgage-backed securitisations, auto loan securitisations, commercial real estate loan origination, structured finance litigation, debt trades, microfinance funding transactions, repacks, and CLOs. Andrzej has advised investors, corporate service providers, originators, arrangers, trustees, servicers, noteholders, and borrowers on a range of structured finance and derivative transactions in a number of jurisdictions.

“I have been very impressed by Andrzej Janiszewski who has been leading an innovative transaction I am involved with. His stand-out contributions are several including pragmatic solutions-driven structuring. This is a multi-party, multi-jurisdictional transaction that requires a lead lawyer to cut through the noise and bring the deal to closure. Relying upon capital markets familiar tools and instruments, Andrzej and the team demonstrate the best of proactive lawyering keeping the client’s objectives as the core driver.” – The Legal 500: Securitisation, 2022.

Experience:

Advising The Global Alliance for Vaccine and Immunizations on a financing agreement to guarantee continued production of the antigen for the first malaria vaccine to be proven safe and effective. GAVI joined forces with GlaxoSmithKline and MedAccess to create this innovative financing structure, with MedAccess sharing the risk of the vaccine not being recommended, and GAVI and GSK being assured of funding for continued production of the antigen. The transaction prevented a shutdown of the facility producing the antigen and prevented the delays of winding down production and having to restart it later if the vaccine pilot proved successful. The RTS,S/AS01e vaccine was recommended by the World Health Organization in October 2021.

Advised on a cross-border impact bond known as the “Utkrisht Bond,” from the Hindi for “Excellence.” The bond aims to reduce the number of mother and baby deaths by improving the quality of maternal care in Rajasthan’s health facilities. The money will be used by service providers to improve access to and quality of care in up to 440 private facilities in Rajasthan,

supporting government efforts to reduce maternal and newborn deaths. Interventions will reach up to 600,000 pregnant women with improved care during delivery.

Advised BRAC International Microfinance on the launch of their transformative international debt programme to tap capital markets for securing reliable and consistent funding that will secure financing for its microfinance operations for the next decade. Establishing a dedicated international financing company for BRAC International Microfinance represents a significant step in BRAC’s evolution. The first debt issuance by the financing company is linked to BRAC International Microfinance’s COVID-19 rebuilding efforts, making liquidity available to households living in poverty in developing countries. Subsequent issuances (backed by loans in other countries in sub-Saharan Africa and Asia) will propel BRAC International Microfinance’s growth in existing and new countries to make financial products and services available to its borrowers and savers that will strengthen their livelihood, well-being, and resilience.

Honors and Awards

Listed as a “Next Generation Partner” in The Legal 500 UK 2026 for ESG